|
HALL A
|
|
|
|
Screening and treating thrombophilia |
| Chairpersons |
Jean Christophe Gris, France
Aharon Lubetsky, Israel |
|
08:30-09:20
08:30
08:50
09:10
|
Debate: Role of low molecular weight heparin in pregnancy complications:
Major: Jean-Christophe Gris, France
Minor: Benjamin Brenner, Israel
Discussion
|
| 09:20-09:40 |
State of the Art: What is the role of thrombophilia in venous thromboembolism?
Aharon Lubetsky, Israel
|
| 09:40-09:50 |
The dominant antithrombin Budapest 3 mutation in the Hungarian population is caused by
a founder effect; genotype-phenotype relations investigated in a large cohort
Zsuzsanna Bereczky, Hungary
|
| 09:50-10:00 |
Inherited thrombophilia in women with unexplained recurrent pregnancy loss or idiopathic infertility: Reproductive friend or foe?
Valeria Raparelli, Italy
|
HALL A
|
|
| 10:30-11:40 |
Pharmacogenomics and thrombolytic therapy
|
| Chairpersons |
Yosef Caraco, Israel
Emilio Clementi, Italy |
|
10:30-10:50
|
State of the Art: Catheter guided thrombolysis for deep vein thrombosis and pulmonary embolism
Alan Bloom, Israel
|
10:50-11:40
10:50
11:10
11:30 |
Debate: Pharmacogenomics in antithrombotic therapy
Advantages: Yosef Caraco, Israel
Limitations: Emilio Clementi, Italy
Discussion
|
| HALL A |
|
16:30-17:40
|
Antiplatelet treatment and its monitoring
|
| Chairpersons |
Marco Cattaneo, Italy
Giovanni Davì, Italy
|
|
16:30-17:20
16:30
16:50
17:10
|
Debate: New antiplatelet agents
Advantages: Giovanni Davì, Italy
Limitations: Marco Cattaneo, Italy
Discussion |
17:20-17:40
|
State of the Art: Monitoring antiplatelet therapy
Marco Cattaneo, Italy
|
|
HALL A
|
|
|
17:40-18:00
|
Immune thrombocytopenic purpura
|
| Chairperson: |
David Varon, Israel
|
|
|
State of the Art: Thrombopoietins for immune thrombocytopenic purpura and beyond
James Bussel, USA
|
Saturday, November 7, 2015
| HALL A |
|
|
|
New oral anticoagulants for the treatment of venous thromboembolism and atrial fibrillation
|
| Chairpersons |
Giancarlo Agnelli, Italy
Benjamin Brenner, Israel
|
|
08:30-09:20
08:30
08:50
09:10
|
Debate: New oral anticoagulants for treatment and prevention of venous thromboembolism
Advantages: Giancarlo Agnelli, Italy
Limitations: Aharon Lubetsky, Israel
Discussion
|
|
09:20-10:10
09:20
09:40
10:00
|
Debate: New oral anticoagulants in cardiology
Advantages: Giovanni Davì, Italy
Limitations: Benjamin Brenner, Israel
Discussion
|
|
10:10-10:20
|
“Real word” initial experience on safety and efficacy with Ticagrelor vs. Clopidogrel in acute coronary syndromes
Michel Butron-Calderon, Spain |
| 10:20-10:30 |
A risk score for prediction of recurrence in patients with unprovoked venousthromboembolism (DAMOVES)
Ana Isabel Franco, Spain
|
| HALL A |
|
|
|
Antithrombotics for patient subgroups
|
| Chairpersons |
Eduardo Arellano-Rodrigo, Spain
Pier M. Mannucci, Italy
|
|
14:00-14:50
14:00
14:20
14:40
|
Debate: Anti thrombotics for atrial fibrillation (AF) in the oldest old
Vitamin K antagonists: Pier M. Mannucci, Italy
Direct oral anticoagulants: Paolo Prandoni, Italy
Discussion
|
|
14:50-15:40
14:50
15:10
15:30
|
Debate: Secondary prophylaxis of thrombosis in myeloproliferative neoplasms
Yes: Eduardo Arellano-Rodrigo, Spain
No: Gunnar Birgegard, Sweden
Discussion
|
| HALL A |
|
|
|
Prevention of venous thromboembolism and coronary artery disease
|
| Chairpersons |
Sergio Coccheri, Italy
Carlo Patrono, Italy
|
|
16:10-17:00
16:10
16:30
16:50
|
Debate: Extended venous thromboembolism prophylaxis
Advantages: Paolo Prandoni, Italy
Limitations: Giancarlo Agnelli, Italy
Discussion
|
17:00-17:50
17:00
17:20
17:40 |
Debate: Primary prevention with aspirin of coronary and cerobrovascular artery disease
Advantages: Carlo Patrono, Italy
Limitations: Sergio Coccheri, Italy
Discussion
|
